Callan JMB Inc. Receives Nasdaq Delisting Warning for Equity Deficiency
Summary
Callan JMB Inc. received a notice from Nasdaq for failing to meet the minimum $2.5 million stockholders' equity requirement, initiating a 45-day period to submit a compliance plan.
Key Events
-
Nasdaq Non-Compliance Notice
The company received a deficiency letter from Nasdaq on April 7, 2026, for non-compliance with Listing Rule 5550(b)(1).
-
Equity Deficiency
Callan JMB Inc. failed to maintain the required minimum of $2,500,000 in stockholders' equity for continued listing on The Nasdaq Capital Market.
-
Compliance Plan Deadline
The company has 45 calendar days, until May 22, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension until October 4, 2026.
-
No Immediate Delisting
The notice does not have an immediate effect on the listing or trading of the company's common stock, which will continue to trade under 'CJMB'.
Analysis
Callan JMB Inc. has received a formal notice from Nasdaq regarding its non-compliance with the minimum $2.5 million stockholders' equity requirement. This is a critical development, especially following the company's recent 10-K filing which disclosed a significant net loss and substantial doubt about its ability to continue as a going concern. While the company has 45 days to submit a compliance plan and potentially an extension until October 2026, failure to regain compliance could lead to delisting, severely impacting liquidity and investor confidence. This notice compounds the existing financial distress signals.
At the time of this filing, CJMB was trading at $1.22 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $1.08 to $5.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.